May 14 (Reuters) - Sanofi said on Wednesday it

plans to invest at least $20 billion to boost manufacturing and

research in the United States through 2030, becoming the latest

drugmaker to scale up its U.S. presence in response to President

Donald Trump's trade policies.

The French drugmaker plans to expand its US manufacturing

capacity, both through direct investments in Sanofi sites, as

well as through partnerships with other domestic manufacturers,

it said.

Its peers such as Roche, Eli Lilly ( LLY ), Johnson

& Johnson ( JNJ ) and Novartis have also announced

large-scale U.S. investments after Trump pushed for more onshore

pharmaceutical manufacturing.